T-group (topology)
284.2.1 Chitinase insertion domain
Ligands and drugs
568
Member domains
247
with ligand contacts (≤ 4 Å)
43.5% of members
214
with DrugDomain annotations
37.7% of members
146
with a DrugBank compound
25.7% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 284.2.1 belongs to X-group 284 FKBP-like, which binds 9.3 ligand superclasses per 20 proteins, broader than 84% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 34 |
| DB04404 | AMI | Allosamizoline | 17 |
| DB18065 | QGB | 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | 6 |
| DB03747 | NGT | N-Acetyl-glucosamine thiazoline | 4 |
| DB00201 | CFF | Caffeine | 3 |
| DB00277 | TEP | Theophylline | 2 |
| DB00806 | PNX | Pentoxifylline | 2 |
| DB01822 | DTD | (4R,5R)-1,2-dithiane-4,5-diol | 2 |
| DB02414 | CHQ | Cyclo(his-pro) | 2 |
| DB03539 | ALI | 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose | 2 |
| DB04115 | BER | Berberine | 2 |
| DB04433 | ALJ | Verpacamide A | 2 |
| DB04541 | GIO | Cyclo(prolylglycyl) | 2 |
| DB00945 | AIN | Acetylsalicylic acid | 1 |
| DB01177 | DM5 | Idarubicin | 1 |
| DB02806 | MXE | 2-Methoxyethanol | 1 |
| DB03109 | — | 2-acetylamino-2-deoxy-b-D-allopyranose | 1 |
| DB03632 | — | — | 1 |
| DB04209 | DEQ | Dequalinium | 1 |
| DB04350 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 24 |
| AMI | ALLOSAMIZOLINE | 19 |
| MGmetal | MAGNESIUM ION | 9 |
| DW0 | 1,1'-PROPANE-1,3-DIYLBIS(3,7-DIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE) | 7 |
| CX9 | 3,7-DIMETHYL-1-[3-(3-METHYL-2,6-DIOXO-9H-PURIN-1-YL)PROPYL]PURINE-2,6-DIONE | 6 |
| QGB | 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-4H-1,2,4-triazol-3-amine | 6 |
| CL | CHLORIDE ION | 5 |
| BV0 | 6-azanyl-11-methyl-2-oxidanylidene-7-[[(2R)-oxolan-2-yl]methyl]-N-(pyridin-3-ylmethyl)-1,9-diaza-7-azoniatricyclo[8.4.0.0^{3,8}]tetradeca-3(8),4,6,9,11,13-hexaene-5-carboxamide | 4 |
| NAmetal | SODIUM ION | 4 |
| NGO | 2-METHYL-4,5-DIHYDRO-(1,2-DIDEOXY-ALPHA-D-GLUCOPYRANOSO)[2,1-D]-1,3-OXAZOLE | 4 |
| NGT | 3AR,5R,6S,7R,7AR-5-HYDROXYMETHYL-2-METHYL-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D]THIAZOLE-6,7-DIOL | 4 |
| PNX | 3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | 4 |
| XZ0 | (2~{S},5~{S})-4-[1-(4-chloranylpyridin-2-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methyl-morpholine | 4 |
| A1L | [2-[[(2S)-1-[bis(phenylmethyl)amino]-5-[[N-(methylcarbamoyl)carbamimidoyl]amino]-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-diazonio-azanide | 3 |
| BU0 | 6-azanyl-2-oxidanylidene-N-[(1S)-1-phenylethyl]-7-(phenylmethyl)-1$l^{4},9-diaza-7-azoniatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaene-5-carboxamide | 3 |
| CAmetal | CALCIUM ION | 3 |
| CFF | CAFFEINE | 3 |
| I5I | 2-(5-isothiocyanato-1-benzofuran-2-yl)-4,5-dihydro-1H-imidazole | 3 |
| SN5 | 2-deoxy-2-(ethanethioylamino)-beta-D-glucopyranose | 3 |
| 3RM | 5-{4-[2-(4-bromophenoxy)ethyl]piperazin-1-yl}-4H-1,2,4-triazol-3-amine | 2 |